^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | derazantinib (ARQ 087) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.
Published date:
02/13/2023
Excerpt:
The current study explored the activity of DZB in patients with mUC and FGFR1-3 GA (NCT04045613)….Confirmed ORR was 8.2% (95% CI 2.2, 19.6) based on 4 PRs (all with FGFR3 S249C mutation/FGFR3 TACC3 fusion) and the DCR was 28.6% (95%CI: 16.6, 43.3).
DOI:
10.1200/JCO.2023.41.6_suppl.501
Trial ID:
